Immunic, Inc. (IMUX)
Stock Price:
$17.44 USD
-2.42 (-12.19%)
Updated November 24, 4:00 PM EST - Market closed
After-hours: $17.54 +0.10 (0.57%) Nov 24, 7:59 PM
Key Info
| Market Cap |
361.33M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-40.55M |
| Shares Out |
20.72M |
| EPS (ttm) |
-3.11 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 24 |
| Last Price |
$17.44 |
| Previous Close |
$19.86 |
| Change ($) |
-2.42 |
| Change (%) |
-12.19% |
| Day's Open |
20.20 |
| Day's Range |
16.09 - 20.98 |
| Day's Volume |
803,248 |
| 52-Week Range |
4.19 - 23.39 |
More Stats
| Market Cap |
361.33M |
| Enterprise Value |
228.88M |
| Earnings Date (est) |
Mar 22, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
20.72M |
| Float |
13.56M |
| EPS (basic) |
-2.95 |
| EPS (diluted) |
-3.11 |
| FCF / Share |
-2.10 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
735,179 |
| Short Ratio |
2.37 |
| Short % of Float |
5.42% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.39 |
| Revenue |
n/a |
| Operating Income |
-42.97M |
| Net Income |
-40.55M |
| Free Cash Flow |
-38.57M |
| Net Cash |
132.45M |
| Net Cash / Share |
6.39 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-26.89% |
| ROE |
-36.30% |
| ROIC |
2,628.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (7)
| Buy |
7 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$60.86*
(248.97% upside)
Low
45.0
Current: $17.44
High
72.0
Target: 60.86
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | - |
| Operating Income | -37.03 | -12.00 | -52.66 | -41.27 | -52.12 | -50.34 | -31.40 | -9.58 |
| Net Income | -34.93 | -11.54 | -52.08 | -40.97 | -52.02 | -47.67 | -32.72 | -6.70 |
| Shares Outstanding | 7.72 | 0.85 | 1.00 | 0.78 | 0.63 | 0.40 | 0.01 | 0.01 |
| Earnings Per Share | -4.52 | -13.63 | -52.40 | -52.40 | -82.80 | -141.60 | -2,994.40 | -715.60 |
| Operating Cash Flow | -28.55 | -9.74 | -40.40 | -35.77 | -49.95 | -40.83 | -28.65 | -9.24 |
| Capital Expenditures | -0.02 | -0.03 | -0.68 | -0.55 | -2.34 | -1.41 | -1.48 | -0.24 |
| Free Cash Flow | -28.56 | -9.77 | -41.08 | -36.33 | -52.29 | -42.23 | -30.13 | -9.49 |
| Cash & Equivalents | 29.37 | 13.07 | 56.90 | 59.99 | 83.95 | 104 | 39.15 | 18.83 |
| Total Debt | 0.52 | - | - | - | - | - | - | - |
| Net Cash / Debt | 28.85 | 13.07 | 56.90 | 59.99 | 83.95 | 104 | 39.15 | 18.83 |
| Assets | 65.96 | 13.37 | 60.38 | 64.03 | 89.08 | 108 | 46.59 | 20.33 |
| Liabilities | 7.59 | 1.92 | 10.34 | 5.58 | 6.76 | 10.52 | 91.24 | 27.96 |
| Book Value | 58.36 | -25.74 | 50.04 | 58.45 | 82.33 | 97.56 | -44.66 | -7.63 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Immunic, Inc. |
| Country |
United States |
| Employees |
26 |
| CEO |
Daniel Vitt |
Stock Information
| Ticker Symbol |
IMUX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMUX |
Description
Immunic, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in Phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in Phase 2 trial to treat Crohn's disease. The company is also developing IMU-935, an inverse agonist of RORgt; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.